NEW YORK (GenomeWeb) – Roche has submitted the Cobas EGFR Mutation Test v2 for premarket approval with the US Food and Drug Administration as a companion diagnostic to AstraZeneca's NSCLC drug AZD9291.
NEW YORK (GenomeWeb) – Roche has submitted the Cobas EGFR Mutation Test v2 for premarket approval with the US Food and Drug Administration as a companion diagnostic to AstraZeneca's NSCLC drug AZD9291.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.